Literature DB >> 7593602

Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice.

S Bellosta1, R W Mahley, D A Sanan, J Murata, D L Newland, J M Taylor, R E Pitas.   

Abstract

apoE deficiency causes hyperlipidemia and premature atherosclerosis. To determine if macrophage-specific expression of apoE would decrease the extent of atherosclerosis, we expressed human apoE in macrophages of apoE-null mice (apoE-/-) and assessed the effect on lipid accumulation in cells of the arterial wall. Macrophage-specific expression of human apoE in normal mice was obtained by use of the visna virus LTR. These animals were bred with apoE-/- mice to produce animals hemizygous for expression of human apoE in macrophages in the absence of murine apoE (apoE-/-,hTgE+/0). Low levels of human apoE mRNA were present in liver and spleen and high levels in lung and peritoneal macrophages. Human apoE was secreted by peritoneal macrophages and was detected in Kupffer cells of the liver. Human apoE in the plasma of apoE-/-,hTgE+/0 mice (n = 30) was inversely correlated (P < 0.005) with the plasma cholesterol concentration. After 15 wk on a normal chow diet, atherosclerosis was assessed in apoE-/-,hTgE+/0 animals and in apoE-/-,hTgE0/0 littermates matched for plasma cholesterol level (approximately 450 mg/dl) and lipoprotein profile. There was significantly less atherosclerosis in both the aortic sinus and in the proximal aorta (P < 0.0001) in the animals expressing the human apoE transgene. In apo-E-/-,hTgE+/0 animals, which had detectable atherosclerotic lesions, human apoE was detected in the secretory apparatus of macrophage-derived foam cells in the arterial wall. The data demonstrate that expression of apoE by macrophages is antiatherogenic even in the presence of high levels of atherogenic lipoproteins. The data suggest that apoE prevents atherosclerosis by promoting cholesterol efflux from cells of the arterial wall.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593602      PMCID: PMC185866          DOI: 10.1172/JCI118271

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells.

Authors:  J A Piedrahita; S H Zhang; J R Hagaman; P M Oliver; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

2.  Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.

Authors:  M F Linton; R Gish; S T Hubl; E Bütler; C Esquivel; W I Bry; J K Boyles; M R Wardell; S G Young
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  Enhanced metabolism of normolipidemic human plasma very low density lipoprotein in cultured cells by exogenous apolipoprotein E-3.

Authors:  S Eisenberg; G Friedman; T Vogel
Journal:  Arteriosclerosis       Date:  1988 Sep-Oct

4.  Synthesis and secretion of apolipoprotein E occur independently of synthesis and secretion of apolipoprotein B-containing lipoproteins in HepG2 cells.

Authors:  S Fazio; Z Yao; B J McCarthy; S C Rall
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

5.  Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice.

Authors:  W S Simonet; N Bucay; R E Pitas; S J Lauer; J M Taylor
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

6.  Regulation of the visna virus long terminal repeat in macrophages involves cellular factors that bind sequences containing AP-1 sites.

Authors:  D H Gabuzda; J L Hess; J A Small; J E Clements
Journal:  Mol Cell Biol       Date:  1989-06       Impact factor: 4.272

7.  Overexpression of apolipoprotein E in transgenic mice: marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia.

Authors:  H Shimano; N Yamada; M Katsuki; M Shimada; T Gotoda; K Harada; T Murase; C Fukazawa; F Takaku; Y Yazaki
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

8.  Hepatic and renal expression of rat apolipoprotein E under control of the metallothionein promoter in transgenic mice.

Authors:  H Shimano; N Yamada; M Shimada; N Ohsawa; C Fukazawa; Y Yazaki; F Takaku; M Katsuki
Journal:  Biochim Biophys Acta       Date:  1991-08-27

9.  Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.

Authors:  N Yamada; I Inoue; M Kawamura; K Harada; Y Watanabe; H Shimano; T Gotoda; M Shimada; K Kohzaki; T Tsukada
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

10.  The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.

Authors:  Y Horie; S Fazio; J R Westerlund; K H Weisgraber; S C Rall
Journal:  J Biol Chem       Date:  1992-01-25       Impact factor: 5.157

View more
  68 in total

1.  Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.

Authors:  M Buttini; M Orth; S Bellosta; H Akeefe; R E Pitas; T Wyss-Coray; L Mucke; R W Mahley
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

Review 2.  Regulation and mechanisms of macrophage cholesterol efflux.

Authors:  Alan R Tall; Philippe Costet; Nan Wang
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

3.  Regulation of lipoprotein metabolism by estrogen in inbred strains of mice occurs primarily by posttranscriptional mechanisms.

Authors:  R A Srivastava; E S Krul; R C Lin; G Schonfeld
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

Review 4.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

5.  The Apolipoprotein E Mimetic Peptide AEM-2 Attenuates Mitochondrial Injury And Apoptosis In Human THP-1 Macrophages.

Authors:  Samantha Giordano-Mooga; Geeta Datta; Paul Wolkowicz; David W Garber; Mayakonda Palgunachari; C Roger White; G M Anantharamaiah
Journal:  Curr Top Pept Protein Res       Date:  2018

6.  Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

Authors:  Taro E Akiyama; Shuichi Sakai; Gilles Lambert; Christopher J Nicol; Kimihiko Matsusue; Satish Pimprale; Ying-Hue Lee; Mercedes Ricote; Christopher K Glass; H Bryan Brewer; Frank J Gonzalez
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

7.  ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma.

Authors:  Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Thomas Gautier; Patrick C N Rensen; Daniel J Rader; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2012-03-01       Impact factor: 5.922

8.  ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium.

Authors:  Nathalie Gaudreault; Nikit Kumar; Jessica M Posada; Kyle B Stephens; Nabora Soledad Reyes de Mochel; Delphine Eberlé; Victor R Olivas; Roy Y Kim; Matthew J Harms; Sean Johnson; Louis M Messina; Joseph H Rapp; Robert L Raffai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-03       Impact factor: 8.311

Review 9.  Hypercholesterolemia links hematopoiesis with atherosclerosis.

Authors:  Oliver Soehnlein; Filip K Swirski
Journal:  Trends Endocrinol Metab       Date:  2012-12-08       Impact factor: 12.015

10.  Influence of PDZK1 on lipoprotein metabolism and atherosclerosis.

Authors:  Olivier Kocher; Ayce Yesilaltay; Ching-Hung Shen; Songwen Zhang; Kathleen Daniels; Rinku Pal; Jianzhu Chen; Monty Krieger
Journal:  Biochim Biophys Acta       Date:  2008-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.